Condition: Melanoma · Melanoma Stage III · Melanoma Stage IV · Sponsor: University of Wisconsin, Madison
The purpose of this research study is to determine if analysis of PET/CT scans and testing of blood samples in people with melanoma that has spread in their body can help researchers determine which patients are more or less likely to respond to immunotherapy and are more or less likely to have side effects. 24 participants will be enrolled and be on study until approximately 4 weeks after their first dose of Immune Checkpoint Inhibitor therapy.
This description comes directly from the study's public registry record.
Cancer Connect · 800-622-8922 · clinicaltrials@cancer.wisc.edu
Always discuss trial participation with your own doctor first.
| University of Wisconsin Hospitals and Clinics (UWHC) | Madison, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06199713